Clinical trials: Squamous Non-Small Cell Lung Cancer (NSCLC)
Maligant Solid Tumor, Head & Neck Cancer
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
This study is a prospective, single-arm, open-label, dose-escalation study. A total of 4 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles.
- Conditions
- Maligant Solid Tumor, Head & Neck Cancer, Thyroid Cancer, Lung Cancer - Non Small Cell Squamous
- Trial name
- NCT07459283
- Testing
- INN805
- Where
- China
- Volunteers
- 10 people
- Sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.
Non-Small-Cell Lung Cancer
A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests.
- Trial name
- NCT01270386
- Testing
- apatinib
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Non-small Cell Lung Cancer, Squamous Cell Carcinoma
Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer
This randomized, multicenter,open-label phase II/III study is to evaluate the effects of chemotherapy combination with autologous cytokine-induced killer Cell immunotherapy in patients with stage IIIb-IV squamous non-small-cell…
- Trial name
- CIK (NCT01631357)
- Testing
- CIK cell, Gemcitabine Injection, Cisplatin injection
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-Small Cell Lung Cancer, Breast Cancer
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
This is a Phase 1b/2, multi-center study to assess the safety and efficacy of ibrutinib in combination with durvalumab (MEDI4736) in participants with relapsed or refractory solid tumors.
- Conditions
- Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- NCT02403271
- Testing
- Ibrutinib, Durvalumab
- Where
- 17 sites in United States
- Volunteers
- 124 people
- Sponsor
- Pharmacyclics LLC.
Non-Squamous Non-Small Cell Lung Cancer
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of this study is to assess the safety, efficacy, pharmacokinetics and immunogenicity of HS-20117 combined with Aumolertinib in…
- Trial name
- NCT06417008
- Testing
- HS-20117, Aumolertinib
- Where
- 2 sites in China
- Volunteers
- 1,080 people
- Sponsor
- Hansoh BioMedical R&D Company
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Advanced Squamous Non-Small Cell Lung Carcinoma
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL
RBN-2397 inhibits PARP7, an enzyme that is switched on by cancer stresses, such as the toxins in cigarette smoke. Cancer cells use PARP7 to hide from the immune system by stopping the cell from sending a signal (Type 1…
- Trial name
- NCT05127590
- Testing
- RBN-2397
- Where
- 19 sites in United States, Israel and 2 more
- Volunteers
- 50 people
- Sponsor
- Ribon Therapeutics, Inc.
Lung Cancer
Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
The purpose of this study is to test a new approach to the use of standard drugs before surgery in patients with lung cancer. This study will find out what effects, good and/or bad, that this approach has on the cancer.
- Trial name
- NCT01443078
- Testing
- pemetrexed, cisplatin, Carboplatin
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer (Squamous or Non Squamous)
Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels
Anti-PD-1 monotherapy has demonstrated significant clinical efficacy in advanced or metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression (tumor proportion score [TPS] >50%), outperforming platinum-based…
- Trial name
- META-1 (NCT07360743)
- Testing
- Pembrolizumab, Cemiplimab
- Where
- 4 sites in France
- Volunteers
- 275 people
- Sponsor
- UNICANCER
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic
MGD019 DART® Protein in Unresectable/Metastatic Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.
- Conditions
- Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer
- Trial name
- NCT03761017
- Testing
- Lorigerlimab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 162 people
- Sponsor
- MacroGenics
Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma.
- Conditions
- Non Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Urothelial Carcinoma, Malignant Mesothelioma
- Trial name
- NCT04173338
- Testing
- Cabozantinib, Pemetrexed
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Augusta University
Non-small Cell Lung Cancer
Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
The purpose of this Phase II, Open-label, single arm, exploratory study is to evaluate the efficacy and the safety of Apatinib（500mg/d）with docetaxel (60 mg/m²) in advanced Non-squamous Non-small cell lung cancer after failure of…
- Trial name
- NCT02780778
- Testing
- Apatinib, Docetaxel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-Squamous Non-Small Cell Neoplasm of Lung
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC
This is a randomized, multicenter, double-blind placebo-controlled phase 3 study of efficacy and safety of BCD-100 in combination with pemetrexed+cisplatin/carboplatin compared to placebo in combination with…
- Trial name
- DOMAJOR (NCT03912389)
- Testing
- BCD-100, Pemetrexed, Cisplatin (or carboplatin)
- Where
- 37 sites in Czechia, Georgia and 4 more
- Volunteers
- 292 people
- Sponsor
- Biocad
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur.
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04032704
- Testing
- ladiratuzumab vedotin, pembrolizumab
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 205 people
- Sponsor
- Seagen Inc.
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
Immunotherapy has become the standard of care in different advanced malignancies. Its effectiveness in the palliative setting was demonstrated by several phase III trials.
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Urothelial Carcinoma
- Trial name
- ICONIC (NCT05229614)
- Testing
- Carbon Ion Therapy, Immunotherapy (Pembrolizumab)
- Where
- 4 sites in Germany, Italy
- Volunteers
- 27 people
- Sponsor
- CNAO National Center of Oncological Hadrontherapy
Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 as a monotherapy or in…
- Conditions
- Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06747585
- Testing
- ALE.P02, Pembrolizumab
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 235 people
- Sponsor
- Alentis Therapeutics AG
Non Small Cell Lung Cancer
Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy
This is an open-label, randomized, non-comparative, multicentre, phase II study in which NSCLC patients who have progressed following chemotherapy and immunoptherapy are randomized to receive treatment with either paclitaxel and…
- Trial name
- ADAPTABLE (NCT05781308)
- Testing
- Paclitaxel, Bevacizumab, Atezolizumab
- Where
- 44 sites in France
- Volunteers
- 156 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Adenocarcinoma AJCC v7
Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer
This phase I trial studies the side effects and best dose of methoxyamine when given together with pemetrexed disodium, cisplatin, and radiation therapy in treating patients with stage IIIA-IV non-small cell lung cancer.
- Conditions
- Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Adenocarcinoma AJCC v7, Stage III Lung Large Cell Carcinoma AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02535325
- Testing
- 3-Dimensional Conformal Radiation Therapy, Cisplatin, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Melanoma, Non-Small Cell Lung Cancer
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
This study is a dose escalation of GR-MD-02 with the standard therapeutic dose of pembrolizumab in patients with advanced melanoma, non-small cell lung cancer, and head and neck squamous cell cancer.
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02575404
- Testing
- GR-MD-02, Pembrolizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Providence Health & Services
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.